Congenital amegakaryocytic thrombocytopenia: genes and variants
Explore variant evidence for Congenital amegakaryocytic thrombocytopenia across 1 analyzed protein (MPL). Linked ClinVar records include 19 pathogenic or likely pathogenic variants, 149 variants of uncertain significance and 17 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-10-15. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Congenital amegakaryocytic thrombocytopenia
MPL: Thrombopoietin receptor
Thrombopoietin signaling through this pathway drives megakaryocyte maturation, platelet production, and hematopoietic stem-cell maintenance. Activating variants can cause myeloproliferative neoplasms or hereditary thrombocytosis, whereas loss-of-function variants cause congenital amegakaryocytic thrombocytopenia.
19 ClinVar pathogenic / likely pathogenic and 166 uncertain variants in MPL have source records linked to Congenital amegakaryocytic thrombocytopenia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Congenital amegakaryocytic thrombocytopenia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MPL P136L | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136H | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136R | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL R257C | 257 | Fibronectin type-III 1 | Pathogenic / likely pathogenic (★★) |
| MPL F104S | 104 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL W435C | 435 | Fibronectin type-III 2 | Pathogenic / likely pathogenic (★★) |
| MPL R102P | 102 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL R102C | 102 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL W154R | 154 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL S505N | 505 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| MPL P635L | 635 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| MPL P106L | 106 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL R257L | 257 | Fibronectin type-III 1 | Pathogenic / likely pathogenic (★) |
| MPL R102H | 102 | Extracellular | Pathogenic / likely pathogenic (★) |
| MPL L254P | 254 | Fibronectin type-III 1 | Pathogenic / likely pathogenic (★) |
| MPL W435R | 435 | Fibronectin type-III 2 | Pathogenic / likely pathogenic (★) |
| MPL R426P | 426 | Fibronectin type-III 2 | Pathogenic / likely pathogenic (★) |
| MPL Y69H | 69 | Extracellular | Pathogenic / likely pathogenic (★) |
| MPL G131R | 131 | Extracellular | Pathogenic / likely pathogenic (★) |
Uncertain variants prioritized for review in Congenital amegakaryocytic thrombocytopenia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| MPL R257H | 257 | Fibronectin type-III 1 | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; R257C at the same position is pathogenic; REVEL 0.811 |
Which prediction tools work for Congenital amegakaryocytic thrombocytopenia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 100 out of 100
- SIFT: 99 out of 100
- REVEL: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 96 out of 100
- CADD: 95 out of 100
- PolyPhen-2: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 91 out of 100
- Pangolin: 66 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 54 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Congenital amegakaryocytic thrombocytopenia
- Thrombocythemia, also linked to MPL
- Essential thrombocythemia, also linked to MPL
- Primary myelofibrosis, also linked to MPL
Frequently asked questions
Which genes have records linked to Congenital amegakaryocytic thrombocytopenia?
This view contains 1 analyzed proteins: MPL. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 19 pathogenic or likely pathogenic variants, 149 variants of uncertain significance and 17 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 243 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center